Related to Stason to Use Lonza’s Gene-Expression System with TNT Antibody Platform

• Kalobios Chooses BioWa and Lonza’s Potelligent CHOK1SV Cell Line
  
• Lonza and California Stem Cell Introduce MotorPlate Human ESC-Derived Motor Neuron Progenitors
  
• Enobia Chooses Lonza for Commercial-Scale Manufacture of Its Enzyme-Replacement Therapy
  
• Lonza to Distribute Roche’s Mycoplasma Testing Solutions
  
• Genesis Signs On Lonza as Production Partner for Cancer Cell Therapy
  
• ArGEN-X Licenses BioWa’s Potelligent Platform to Generate More Potent Antibodies
  
• Lonza to Deimmunize ImmuneMed’s Virus Suppressing Factor
  
• Lonza to Carry Out Process Development for Immutep’s Lead Cancer Immunotherapy
  
• Agennix Contracts Lonza for Commercial Manufacturing of Its Oral NSCLC Immunotherapy
  
• Lonza, Avalanche Partner on Baculovirus-Based AAV Manufacturing Platform
  
• RuiYi, CMC Collaborate to Speed mAb Development
  
• RuiYi Licenses mAb Development to China's Genor
  
• Lonza to Manufacture Elusys’ Antianthrax mAb
  
• Elusys Extends Manufacturing Agreement with Lonza for Its Anthrax Treatment
  
• Daiichi Sankyo Becomes First Firm to License BioWa and Lonza’s Fucose-Free mAb Cell Line
  
• Lonza Provides GSK with Manufacturing Capacity for Five Clinical-Stage mAbs
  
• Lonza to Manufacture Genmab’s Tissue Factor-Targeting Antibody-Drug Conjugate
  
• Lonza to Manufacture OncoMed’s Anticancer Antibody Pipeline
  
• Lonza to Provide Cell-Line and Process-Development Services for Athera’s mAb
  
• FivePrime Licenses BioWa, Lonza’s Cell Line for Anticancer Antibody Pipeline